Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.358 | Optical Coherence Tomography evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris | Prof. YAN Bryan Ping Yen |
| 2016.319 | Investigation on the novel noninvasive sensors and algorithms for validating cuffless continuous blood pressure measurement. |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.509 | Hong Kong Percutaneous Coronary Intervention Registry |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.370 | Patient education, monitoring and support to enhance adherence to dabigatran in patients with non-valvular atrial fibrillation |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.301 | Effects of Cardiovascular Autonomic Nervous System Activities on BP/ECG/PPG/Respiratory Related Physiological Features, Validation of Improved PTT-based Cuffless BP Estimation with IEEE 1708 Standard, and Measurement of Respiratory Rate with a Novel Method |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.490 | Development of personalized medicine using Prenetics iGenes pharmacogenomic panel to predict individual responses to cardiovascular drugs |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2017.366 | ACCelerated ThrombolySiS for Post-Thrombotic Syndrome Using the EKOS System |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.265 | The Effect of CYP2C19 Genetic Variants on Clinical Outcomes in Post-Angioplasty Patients Treated with Clopidogrel |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.542 | East Asian ALDH2 polymorphism and impact on myocardial infarct size |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2014.603 | HK-GP AF Screening & Education Program | Prof. YAN Bryan Ping Yen |
| 2014.381 | Multinational Abluminal Sirolimus Coated BiO-Engineered StenT – The MASCOT Post Marketing Registry | Dr. YAN Bryan Ping Yen |
| 2015.638 | Defining the athletes heart phenotype: A comparison of male Caucasian and East Asian elite footballers and rugby players |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2014.258 | A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo | Prof. YAN Bryan Ping Yen |
| 2017.003 | Implantation of the Venus P-ValveTM in the Pulmonic Position in Patients with Native Outflow Tracts |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2014.653 | Changing Pattern of Revascularization for Critical Limb Ischemia towards an Endovascular First Approach in Hong Kong | Prof. YAN Bryan Ping Yen |
| 2015.302 | ASTRI Wireless ECG Module Public Trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.292 | A novel non-invasive radial artery tonometric cardiovascular monitoring device for assessment of vascular aging, subclinical atherosclerosis and cardiovascular risk in the elderly. |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.630 | Renal Artery Sympathetic Denervation by Catheter Ablation after Pulmonary Vein Isolation (PVI) for Persistent Atrial Fibrillation |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.296 | International Survey on Current Status & Future of Drug-Eluting Stents |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.297 | Optical Coherence Tomography evaluation of Very Early eNdothelialization after Dual Therapy Drug-eluting Stent with EPC CaptURE (OCT-VENTURE) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.291 | Optimal Bioabsorbable Vascular Scaffold Technique for Complex Bifurcation Lesions |
Dr. YAN Bryan Ping Yen 甄秉言 |
| 2016.623 | Pharmacoepidemiology and pharmacoeconomics of oral anticoagulation therapy in Hong Kong | Dr. YAN Bryan Ping Yen |
| 2017.234 | PWH Cardiac Implantable Electronic Devices (CIED) Home Monitoring Registry |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.468 | AI-Based Intima-Media Thickness Measurement for Cardiovascular Risk Assessment |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2025.242 | A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial | Prof. YAN Bryan Ping Yen |
| 2024.339 | Investigations of cardiotoxicity in cancer survivors | Prof. YAN Bryan Ping Yen |
| 2024.251 | BIOTRONIK – Safety and Clinical Performance of the Drug Eluting Resorbable Coronary MAGnesium Scaffold System (Freesolve) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A randomized controlled trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.152 | Rationale and design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.156 | A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.212 | Retrospective Database Study for Treatment Patterns of Lipid-lowering Therapy in Patients with Hypercholesterolemia or Mixed Dyslipidemia in Hong Kong, South Korea, and Taiwan (READY Study) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.004 | Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2020.154 | BIOFLOW-DAPT: BIOTRONIK – A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual AntiPlatelet Therapy |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.346 | HD Mapping Observational Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.304 | Achievement of cardiovascular risk factor goals and target levels in patients at very-high and high cardiovascular risk in Hong Kong |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.299 | Lipid management status of patients with ischemic stroke (IS) in Hong Kong | Prof. YAN Bryan Ping Yen |
| 2019.357 | Prolonged Ambulatory Heart Rate Variability Monitoring to Predict Major Adverse Cardiac Events in High-risk Patients with Cardiovascular Diseases |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.442 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.448 | Rationale and Design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): A Randomized, Open-label study |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2018.382 | ILUMIEN IV: OPTIMAL PCI OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation Compared to Angiography: a Multicenter Randomized TriaL in PCI |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.080 | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2018.393 | Validation of a cuffless blood pressure device for 24-hours ambulatory blood pressure monitoring |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.571 | Gaps In Awareness of Peripheral Arterial Disease in Hong Kong: A Cross Sectional Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.653 | In-Depth Analyses of 12-lead ECG P-wave Indices Using Machine Learning to Predict Atrial Fibrillation and Cardiovascular Events |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.214 | XIENCE 28 Global Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.215 | Electrical Activation Mapping Guided Cardiac Resynchronization Therapy for Nonresponders | Prof. YAN Bryan Ping Yen |
| 2018.068 | A nurse-coordinated integrated care model to support decision-making and self-care in patients with atrial fibrillation: A randomized controlled trial | Prof. YAN Bryan Ping Yen |
| 2019.021 | Activation Pattern and Acute Hemodynamics of His and Left Bundle Pacing | Prof. YAN Bryan Ping Yen |
| 2020.082 | A Non-randomized, Clinical Registry of the DynamX Novolimus Eluting Coronary Bioadaptor System in the Treatment of Patients with De Novo Native Coronary Artery Lesions |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2023.296 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK‑0616 in Adults With Heterozygous Familial Hypercholesterolemia |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.041 | A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT) |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
Page 248 of 265.